Media reports have focused on 23andMe’s celebrity customers and glitzy "spit parties." But the Google-backed direct-to-consumer genetic testing company is after something beyond selling spit kits: It hopes to compile huge amounts of genetic and other data that it can re-sell to biotech and drug company researchers. From Mother Jones online, 3 November 2008.